Application of pyrroloquinoline quinone to medicines resistant to asthma and allergic reaction

A pyrroloquinoline quinone and allergy technology, which can be applied to drug combinations, medical preparations containing active ingredients, and pharmaceutical formulations, etc., can solve problems such as high cost, and achieve alleviation of airway inflammation, allergy, and strong anti-oxidation. and anti-inflammatory effects

Inactive Publication Date: 2020-11-06
ZHONGSHAN HOSPITAL FUDAN UNIV
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Current anti-IgE therapy (omalizumab), anti-IL-5 therapy (mepolizumab, reslizumab, and benralizumab), and anti-IL-4 / 13 therapy can significantly improve asthma control in patients with severe asthma , reduce the number of acute exacerbations, but only for patients with specific endotypes, and the cost is expensive

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of pyrroloquinoline quinone to medicines resistant to asthma and allergic reaction
  • Application of pyrroloquinoline quinone to medicines resistant to asthma and allergic reaction
  • Application of pyrroloquinoline quinone to medicines resistant to asthma and allergic reaction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0022] The synthesis of pyrroloquinoline quinone (PPQ) requires 7 genes, which are pyrroloquinoline quinone A to G genes, as shown in Table 1.

[0023] Table 1

[0024] PQQ synthetic gene Features wxya Provides precursors for PQQ biosynthesis wxya Modify the existing transporter to realize the transport of PQQ from the plasma membrane to the cytoplasm wxya Enzymes that catalyze the last step in the synthesis of PQQ wxya Necessary enzyme, function is not yet clear wxya Cofactor for PQQ synthesis reaction wxya It is cleaved from the pqqA precursor after the precursor completes cyclization wxya It is cleaved from the pqqA precursor after the precursor completes cyclization

[0025] The synthetic process of pyrroloquinoline quinone:

[0026] The raw materials are tyrosine and glutamic acid, which constitute the basic skeleton of the ring structure of pyrroloquinoline quinone. The synthesis process is as follows:

[...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of pyrroloquinoline quinone to medicines resistant to asthma and allergic reaction. Pyrroloquinoline quinone can relieve allergic airway inflammation through antioxidant and anti-inflammatory effects, and is a potential novel medicine for the treating asthma. Pyrroloquinoline quinone has high antioxidant and anti-inflammatory effects. The in-vivo and in-vitrostudies carried out by the invention show that pyrroloquinoline quinone can reduce allergic airway inflammation by improving the immune microenvironment and regulating a JAK-STAT signaling pathway, and research shows that pyrroloquinoline quinone is safe for oral administration, so that pyrroloquinoline quinone is a potential novel medicine for treating asthma. Pyrroloquinoline quinone exists naturally in nature and can be supplemented by diet, the safety is good, the side effects are low, and the accessibility is high. Pyrroloquinoline quinone is a non-glucocorticoid immunomodulator that targets an asthma inflammatory pathway, the mechanism of medicine action is different from that of current medicines for treating asthma, and mutual complementing can be carried out.

Description

technical field [0001] The invention relates to the application of pyrroloquinoline quinone in anti-asthma and allergy drugs, and belongs to the technical field of pharmaceutical preparations containing organic active ingredients. Background technique [0002] Asthma is a heterogeneous disease characterized by chronic airway inflammation, and oxidative stress plays an important role in its development. Asthma patients have elevated levels of oxidation and reduced antioxidant mechanisms. Existing studies have found that the intervention of some substances with antioxidant effects in animal models of asthma can effectively prevent or antagonize oxidative stress damage, which is of great significance in the treatment of asthma. [0003] Glucocorticoids are the most effective anti-inflammatory drugs in the treatment of asthma. These drugs work by inhibiting most steps of the cascade of inflammatory responses. However, it is now clear that asthma is a syndrome with many differe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4745A61P11/06A61P37/02
CPCA61K31/4745A61P11/06A61P37/02
Inventor 陈智鸿程韵枫周洁白闵智慧徐侃邓至曾瑜真毛若琳崔博
Owner ZHONGSHAN HOSPITAL FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap